Ami Asset Management Has Increased By $1.54 Million Its Anika Therapeutics Com (ANIK) Stake; Profile of 3 Analysts Covering Bioblast Pharma Ltd (ORPN)

July 13, 2017 - By Clifton Ray

Among 3 analysts covering Bio Blast Pharma (NASDAQ:ORPN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio Blast Pharma had 5 analyst reports since August 24, 2015 according to SRatingsIntel. Rodman & Renshaw initiated Bioblast Pharma Ltd (NASDAQ:ORPN) rating on Thursday, January 28. Rodman & Renshaw has “Buy” rating and $25.0 target. Roth Capital maintained it with “Buy” rating and $25 target in Monday, August 24 report. As per Wednesday, December 9, the company rating was maintained by Roth Capital. The firm has “Hold” rating given on Tuesday, August 25 by Zacks. The stock of Bioblast Pharma Ltd (NASDAQ:ORPN) has “Buy” rating given on Wednesday, December 9 by TH Capital. See Bioblast Pharma Ltd (NASDAQ:ORPN) latest ratings:

Ami Asset Management Corp increased Anika Therapeutics Inc Com (ANIK) stake by 11.26% reported in 2016Q4 SEC filing. Ami Asset Management Corp acquired 32,162 shares as Anika Therapeutics Inc Com (ANIK)’s stock declined 3.98%. The Ami Asset Management Corp holds 317,885 shares with $15.56 million value, up from 285,723 last quarter. Anika Therapeutics Inc Com now has $677.49M valuation. The stock increased 0.87% or $0.4 during the last trading session, reaching $46.17. About shares traded. Anika Therapeutics Inc (NASDAQ:ANIK) has risen 4.53% since July 13, 2016 and is uptrending. It has underperformed by 12.17% the S&P500.

Ami Asset Management Corp decreased Exlservice Holdings Inc. (NASDAQ:EXLS) stake by 13,692 shares to 257,090 valued at $12.97 million in 2016Q4. It also reduced Kimberly Clark Corp (NYSE:KMB) stake by 14,527 shares and now owns 189,154 shares. Healthcare Svcs Gp Inc Com (NASDAQ:HCSG) was reduced too.

Investors sentiment decreased to 1.01 in 2016 Q4. Its down 0.25, from 1.26 in 2016Q3. It dropped, as 17 investors sold ANIK shares while 53 reduced holdings. 20 funds opened positions while 51 raised stakes. 10.86 million shares or 0.92% less from 10.97 million shares in 2016Q3 were reported. Pdt Ptnrs Limited Co stated it has 22,400 shares or 0.07% of all its holdings. Guggenheim Cap Lc has 0% invested in Anika Therapeutics Inc (NASDAQ:ANIK) for 4,779 shares. Moreover, Assetmark has 0% invested in Anika Therapeutics Inc (NASDAQ:ANIK). Voya Inv Mgmt Lc holds 0% or 17,250 shares in its portfolio. Moreover, Acadian Asset Management Ltd Com has 0.01% invested in Anika Therapeutics Inc (NASDAQ:ANIK). Goldman Sachs Gru stated it has 44,425 shares. Portolan Mgmt Limited Com holds 0.45% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK) for 67,892 shares. Park Circle Co reported 10,000 shares. Calvert Invest Inc holds 0.11% or 61,974 shares. D E Shaw Incorporated invested 0.01% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK). Navellier Incorporated accumulated 6,423 shares or 0.05% of the stock. Thompson Siegel And Walmsley Limited Liability Com has invested 0.32% in Anika Therapeutics Inc (NASDAQ:ANIK). Creative Planning has 0% invested in Anika Therapeutics Inc (NASDAQ:ANIK). Mcf Advsrs Llc holds 250 shares. Tci Wealth Advsr reported 0% stake.

Among 3 analysts covering Anika Therapeutics (NASDAQ:ANIK), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Anika Therapeutics had 6 analyst reports since July 30, 2015 according to SRatingsIntel. Northland Capital maintained it with “Outperform” rating and $57 target in Thursday, July 30 report. Zacks upgraded Anika Therapeutics Inc (NASDAQ:ANIK) on Wednesday, August 26 to “Hold” rating. Northland Capital maintained the stock with “Outperform” rating in Friday, February 26 report. The rating was downgraded by Northland Capital to “Market Perform” on Wednesday, April 27. Barrington Research initiated Anika Therapeutics Inc (NASDAQ:ANIK) rating on Monday, October 12. Barrington Research has “Outperform” rating and $39 target. On Friday, August 28 the stock rating was initiated by First Analysis with “Equal Weight”.

Since February 22, 2017, it had 0 insider purchases, and 3 sales for $833,696 activity. On Wednesday, February 22 the insider LAND RAYMOND J sold $129,326. Cheung Sylvia also sold $196,096 worth of Anika Therapeutics Inc (NASDAQ:ANIK) shares. $508,274 worth of Anika Therapeutics Inc (NASDAQ:ANIK) was sold by Thompson Jeffery S on Friday, May 19.

The stock decreased 6.73% or $0.041 on July 12, reaching $0.564. About shares traded. Bioblast Pharma Ltd (NASDAQ:ORPN) has declined 69.59% since July 13, 2016 and is downtrending. It has underperformed by 86.29% the S&P500.

Investors sentiment increased to 0.71 in 2016 Q4. Its up 0.04, from 0.67 in 2016Q3. It improved, as 2 investors sold Bioblast Pharma Ltd shares while 5 reduced holdings. 2 funds opened positions while 3 raised stakes. 1.68 million shares or 3.63% more from 1.62 million shares in 2016Q3 were reported. Morgan Stanley holds 0% or 513 shares. New Jersey-based Sabby Mngmt Limited Co has invested 0.04% in Bioblast Pharma Ltd (NASDAQ:ORPN). Hightower Advisors Limited Liability Company has 0% invested in Bioblast Pharma Ltd (NASDAQ:ORPN) for 24,000 shares. California Public Employees Retirement System has invested 0% in Bioblast Pharma Ltd (NASDAQ:ORPN). Blackrock Inv Mngmt Ltd Com owns 1,255 shares or 0% of their US portfolio. Wells Fargo Communications Mn stated it has 1,000 shares. Deutsche Bancorporation Ag owns 1 shares. Oppenheimer & stated it has 24,700 shares. Knoll Cap Management Limited Partnership has 206,054 shares. Blackrock Institutional Na accumulated 152,906 shares. Citadel Advsrs Limited Liability Company holds 0% of its portfolio in Bioblast Pharma Ltd (NASDAQ:ORPN) for 24,177 shares. 163,811 were reported by Bridgeway Cap Management Incorporated. Renaissance Technology Ltd Liability Corp reported 0% in Bioblast Pharma Ltd (NASDAQ:ORPN). Kcg Hldg Inc holds 0% or 15,032 shares in its portfolio. Blackrock Fund invested in 0% or 16,786 shares.

Bioblast Pharma Ltd is an Israel development-stage biopharmaceutical company. The company has market cap of $10.31 million. The Firm is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It currently has negative earnings. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.